{"id":"NCT00586664","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2008-01-04","resultsPosted":"2012-03-26","lastUpdate":"2013-02-08"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Bepreve (bepotastine besilate ophthalmic solution) 1.5%","otherNames":[]},{"type":"DRUG","name":"placebo comparator","otherNames":[]},{"type":"DRUG","name":"Bepotastine Besilate Ophthalmic Solution 1.0%","otherNames":[]}],"arms":[{"label":"Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%","type":"EXPERIMENTAL"},{"label":"Bepotastine Besilate Ophthalmic Solution 1.0%","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis","primaryOutcome":{"measure":"Ocular Itching","timeFrame":"15 minutes, 8 hours & 16 hours post-dose from Conjunctival Allergen Challenge (CAC) Model","effectByArm":[{"arm":"Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%","deltaMin":0.4,"sd":0.6},{"arm":"Placebo","deltaMin":1.9,"sd":1},{"arm":"Bepotastine Besilate Ophthalmic Solution 1.0%","deltaMin":0.4,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22991696","20488431"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Nasopharyngitis"]}}